CGRP Forum
Send to a colleague
Register
Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

News from the CGRP Forum

ACHIEVE II meets primary endpoints with ubrogepant 50mg in acute migraine treatment

Significantly more migraine patients were free of pain and the most bothersome migraine symptoms, two hours after taking the oral CGRP inhibitor, ubrogepant 50mg, than those treated with placebo. These were the key findings reported by investigators taking part in the Phase 3, ACHIEVE II trial.

Read the full report here »


Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Amgen Novartis
© Copyright CGRP Forum 2018. Please click here to unsubscribe from future mailings.
‚Äč